目的探讨贝伐珠单抗联合TC(紫杉醇/卡铂)方案治疗晚期复发性卵巢癌患者的效果。方法选取2017年11月至2022年11月汉中市中心医院收治的92例复发性晚期卵巢癌患者进行随机对照试验,采用随机数字表法将其分为对照组和观察组,各46例。对照...目的探讨贝伐珠单抗联合TC(紫杉醇/卡铂)方案治疗晚期复发性卵巢癌患者的效果。方法选取2017年11月至2022年11月汉中市中心医院收治的92例复发性晚期卵巢癌患者进行随机对照试验,采用随机数字表法将其分为对照组和观察组,各46例。对照组年龄(52.34±8.45)岁,国际妇产科联盟(International Federation of Gynecology and Obstetrics,IFGO)分期Ⅲ期24例、Ⅳ期22例。观察组年龄(53.21±9.67)岁,FIGO分期Ⅲ期23例、Ⅳ期23例。对照组采用TC方案治疗,观察组在对照组基础上加用贝伐珠单抗治疗;两组均治疗6个周期,约18周。对比两组患者治疗后临床疗效、肿瘤血清标志物[糖类抗原125(carbohydrate antigen 125,CA125)、人附睾蛋白4(human epididymis protein 4,HE4)、糖类抗原199(carbohydrate antigen 199,CA199)、血管内皮生长因子(vascular endothelial growth factor,VEGF)]水平、治疗后1年生存率、生存质量[采用卡氏功能状态量表(Karnofsky Performance Status Scale,KPS)]评分和不良反应发生情况。采用t检验、χ^(2)检验。结果治疗6个周期后,观察组疾病缓解率为78.26%(36/46),高于对照组的54.35%(25/46)(χ^(2)=7.771,P=0.005);观察组CA125、HE4、CA199和VEGF水平均低于对照组(均P<0.05);观察组治疗后1年生存率为73.91%(34/46),高于对照组46.65%(21/46)(χ^(2)=7.640,P=0.006);观察组KPS评分为(72.52±8.13)分,高于对照组的(64.60±7.58)分(t=4.832,P<0.001);两组主要不良反应为骨髓抑制、消化道反应和肝肾损伤;观察组与对照组各不良反应发生率相比,差异均无统计学意义(均P>0.05)。结论贝伐珠单抗联合TC方案治疗复发性晚期卵巢癌患者临床效果较好,可提高患者1年生存率和生活质量,降低肿瘤血清标志物水平,且不良反应可控。展开更多
Premature Ovarian Failure (POF) is cessation of ovarian functions before the age of 40 years with consequent cessation of menstruation. The objective of study was therefore to evaluate the emotional reaction and self-...Premature Ovarian Failure (POF) is cessation of ovarian functions before the age of 40 years with consequent cessation of menstruation. The objective of study was therefore to evaluate the emotional reaction and self-efficacy of women with POF. Forty-two women confirmed to have Premature Ovarian Failure seen at the outpatient clinic of Maternity Hospital fulfilled the study criteria, were enrolled into the study. Another group of 42 healthy women formed the control group. The instrument of data collection included three types of questionnaires to assess the depth of emotional reaction to the diagnosis of POF including the subjects’ biodata, modified Health Orientation Scale (HOS) and Stanford Chronic Disease Self-Efficacy Scale. The women with POF presented at the clinic with infertility (P P P < 0.05). The diagnosis of ovarian insufficiency was a traumatic life event similar to bereavement (grieving of no obvious loss to others), with high level of anxiety, depression, fear of divorce, lower life satisfaction and impaired self-esteem. Fertility was generally of profound concern to all of them, because fertility was a societal landmark of womanhood and youth. The Stanford Chronic Self Efficacy scores were generally low (below 7) in coping with emotion reaction to loss of fertility, loss of menstruation, loss of self-esteem and other significant emotional reactions. The present study has demonstrated that Premature Ovarian Failure is associated with severe emotional distress and impaired ability to cope with them especially low self-esteem. A multidisciplinary management team is advocated for POF.展开更多
文摘目的探讨贝伐珠单抗联合TC(紫杉醇/卡铂)方案治疗晚期复发性卵巢癌患者的效果。方法选取2017年11月至2022年11月汉中市中心医院收治的92例复发性晚期卵巢癌患者进行随机对照试验,采用随机数字表法将其分为对照组和观察组,各46例。对照组年龄(52.34±8.45)岁,国际妇产科联盟(International Federation of Gynecology and Obstetrics,IFGO)分期Ⅲ期24例、Ⅳ期22例。观察组年龄(53.21±9.67)岁,FIGO分期Ⅲ期23例、Ⅳ期23例。对照组采用TC方案治疗,观察组在对照组基础上加用贝伐珠单抗治疗;两组均治疗6个周期,约18周。对比两组患者治疗后临床疗效、肿瘤血清标志物[糖类抗原125(carbohydrate antigen 125,CA125)、人附睾蛋白4(human epididymis protein 4,HE4)、糖类抗原199(carbohydrate antigen 199,CA199)、血管内皮生长因子(vascular endothelial growth factor,VEGF)]水平、治疗后1年生存率、生存质量[采用卡氏功能状态量表(Karnofsky Performance Status Scale,KPS)]评分和不良反应发生情况。采用t检验、χ^(2)检验。结果治疗6个周期后,观察组疾病缓解率为78.26%(36/46),高于对照组的54.35%(25/46)(χ^(2)=7.771,P=0.005);观察组CA125、HE4、CA199和VEGF水平均低于对照组(均P<0.05);观察组治疗后1年生存率为73.91%(34/46),高于对照组46.65%(21/46)(χ^(2)=7.640,P=0.006);观察组KPS评分为(72.52±8.13)分,高于对照组的(64.60±7.58)分(t=4.832,P<0.001);两组主要不良反应为骨髓抑制、消化道反应和肝肾损伤;观察组与对照组各不良反应发生率相比,差异均无统计学意义(均P>0.05)。结论贝伐珠单抗联合TC方案治疗复发性晚期卵巢癌患者临床效果较好,可提高患者1年生存率和生活质量,降低肿瘤血清标志物水平,且不良反应可控。
文摘Premature Ovarian Failure (POF) is cessation of ovarian functions before the age of 40 years with consequent cessation of menstruation. The objective of study was therefore to evaluate the emotional reaction and self-efficacy of women with POF. Forty-two women confirmed to have Premature Ovarian Failure seen at the outpatient clinic of Maternity Hospital fulfilled the study criteria, were enrolled into the study. Another group of 42 healthy women formed the control group. The instrument of data collection included three types of questionnaires to assess the depth of emotional reaction to the diagnosis of POF including the subjects’ biodata, modified Health Orientation Scale (HOS) and Stanford Chronic Disease Self-Efficacy Scale. The women with POF presented at the clinic with infertility (P P P < 0.05). The diagnosis of ovarian insufficiency was a traumatic life event similar to bereavement (grieving of no obvious loss to others), with high level of anxiety, depression, fear of divorce, lower life satisfaction and impaired self-esteem. Fertility was generally of profound concern to all of them, because fertility was a societal landmark of womanhood and youth. The Stanford Chronic Self Efficacy scores were generally low (below 7) in coping with emotion reaction to loss of fertility, loss of menstruation, loss of self-esteem and other significant emotional reactions. The present study has demonstrated that Premature Ovarian Failure is associated with severe emotional distress and impaired ability to cope with them especially low self-esteem. A multidisciplinary management team is advocated for POF.
